Novartis was the first pharmaceutical company with a global leadership position in both patented prescription and generic pharmaceuticals.
Sandoz plays a critical role in the Novartis strategy of offering a complete range of treatment options to patients, physicians and healthcare providers worldwide. This broad portfolio helps to make affordable, high-quality medicines available to patients world-wide and helps stabilize healthcare systems around the world as governments face increasing cost containment pressures.
Two main elements empower the Sandoz business strategy:
- Global reach and reputation: In addition to its unique position within Novartis, Sandoz benefits from a strong global presence and powerful brand recognition worldwide.
- Unique expertise: Sandoz distinguishes itself primarily through its ability to develop, produce and commercialize differentiated medicines. Sandoz is the pioneer and global leader of biosimilars — follow-on versions of biopharmaceuticals following patent expiry — with the first three approved and marketed products in the EU (human growth hormone Omnitrope, anemia medicine Binocrit / epoetin alfa Hexal, and oncology medicine Zarzio / Filgrastim Hexal).
Sandoz - adding value through four key differentiated pillars
Sandoz differentiates itself through its ability to develop, produce and commercialize complex, value-added products. The company specializes in complex, differentiated products with a focus on biosimilars, injectables, inhalables, ophthalmics and other difficult-to-make generics.
For additional information please roll-over the Sandoz graphic below.
High-quality, clinically-proven alternatives to existing biologics which offer comparable safety and efficacy at a more affordable price. Sandoz pioneered and clearly leads the way in this field with three marketed biosimilars. This accounts for over half of the total biosimilar market segment in the combined markets of North America, Europe, Japan and Australia.
Non-biologic drugs taken via injection including affordable, state-of-the-art generic medicines. Following the acquisition of EBEWE Pharma and the blockbuster success of generic enoxaparin, Sandoz is the clear global #1 in this field.
High-quality medicines that target the anatomy, physiology and diseases of the eye. With the addition of Falcon's broad line of generic ophthalmic and optic products, Sandoz is now the global generics leader in this differentiated field.
In this challenging regulatory environment, complex drugs are combined with sophisticated delivery devices to meet a rapidly growing demand for affordable new options to treat asthma and COPD (chronic obstructive pulmonary disease). With a rich pipeline, Sandoz holds a strong global #5 position in this area. Over time it aims to achieve a leadership position to complement its leadership positions in the other strategic areas.
Strong generic dermatology development and manufacturing expertise, particularly in the area of semi-solid forms such as creams and ointments, as well as a well-known branded business, PharmaDerm, which markets over 60 FDA-approved topical therapies in the US. Sandoz is the global leader in this area.
Sandoz holds the #1 position in the market in this area and is a fully-integrated provider of affordable, high-quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms.